Business context and reporting period
Filing identity: The supplied filing is Catalyst Biosciences, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2023—not a filing identified as Gyre Therapeutics, Inc. Investors should verify the issuer before relying on this summary.
Catalyst had stopped its prior research and development programs and sold its complement and rare bleeding disorder assets. It acquired rights outside China to F351 (hydronidone), a clinical-stage candidate for liver fibrosis, in December 2022, and was pursuing a proposed transaction to acquire an indirect controlling interest in China-based Beijing Continent Pharmaceutical (BC).
Key financial metrics
Amounts below are in U.S. dollars; financial statement amounts are converted from thousands to millions.
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | $0 | $0.794 million collaboration revenue |
| Research and development expense | $0.588 million | $9.703 million |
| General and administrative expense | $3.970 million | $4.994 million |
| Gain on asset disposal | $4.736 million | None reported |
| Net income (loss) | $0.260 million | $(14.536) million |
| Cash used in operating activities | $6.216 million | $12.050 million |
| Cash and cash equivalents at period end | $8.099 million | $21.666 million at December 31, 2022 |
The quarter’s small profit reflected the $4.736 million net gain from selling legacy bleeding-disorder assets, not recurring product revenue. No drug products were approved for sale, and the filing reported no debt. At March 31, current assets were $14.014 million and current liabilities were $6.844 million; total liabilities were $11.394 million. The balance sheet also included a $4.550 million long-term receivable from GCBP and $9.550 million of current and noncurrent CVR derivative liabilities.
Material changes versus the prior comparable period
- Revenue ended after termination of the Biogen collaboration: Q1 2023 revenue was zero versus $0.794 million in Q1 2022.
- R&D expense fell 94% to $0.588 million, reflecting cessation of legacy programs and sharply reduced activity. Management said it did not expect material R&D expense before the proposed business combination closes.
- G&A expense decreased 21% to $3.970 million.
- Operating cash use improved to $6.216 million from $12.050 million, but cash declined by $13.567 million during Q1, principally including the $7.764 million of dividend and CVR distributions.
Outlook, risks and unusual items
- Going concern and preferred-stock conversion: Management said cash was expected to fund operations for at least 12 months assuming stockholders approve conversion of the Series X preferred stock. The filing nevertheless disclosed substantial doubt about the company’s ability to continue as a going concern because the vote is outside its control. If conversion is not approved by September 30, 2023, holders may seek cash redemption; using the May 8 share price of $0.21, the filing estimated a potential payment of approximately $25.9 million, which the company said it could not fund with available liquidity.
- Proposed BC transaction: Closing required stockholder approval, expected in Q3 2023, and other conditions. If completed, Catalyst could issue up to 1,110,776,224 common shares for an indirect controlling interest in BC. Termination in specified circumstances could trigger a $2.0 million fee and reimbursement of expenses up to $2.0 million.
- Nasdaq listing risk: The company reported failures to meet Nasdaq’s minimum bid-price and stockholders’ equity requirements and said it had requested a hearing. Delisting could harm share liquidity, financing access, and the proposed transaction; continued listing or satisfaction of initial-listing requirements was not assured.
- Asset-sale proceeds and CVRs: The GCBP sale provided $1.0 million upfront, with a $5.0 million holdback expected in 2025 subject to indemnification conditions. The Vertex sale’s $5.0 million holdback was expected in Q2 2023, also subject to conditions. Net proceeds are generally payable to CVR holders, not available as unrestricted operating cash.
- Other risks and commitments: The filing cited possible bank-access and financing risks, potential COVID-19 disruption to F351 development, and no material legal proceedings. Subsequent to quarter-end, GNI agreed to pay certain F351 development costs before the business combination closes, subject to reimbursement afterward; manufacturing agreements involved payments of up to $0.5 million combined.
Important facts for investors to verify
- Confirm that Catalyst Biosciences—not Gyre Therapeutics—is the intended issuer and verify the applicable filing.
- Check the outcome and terms of stockholder votes on preferred-stock conversion and the proposed BC transaction, including any required cash redemption or dilution.
- Verify Nasdaq hearing and listing status and whether the combined company can meet applicable listing requirements.
- Track actual cash burn, available unrestricted cash, and the timing and conditions for Vertex and GCBP holdback receipts and CVR distributions.
- Assess F351 development progress, GNI cost-sharing and reimbursement obligations, and the company’s financing needs if the transaction is delayed or does not close.